^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Ornithine decarboxylase inhibitor

    Related drugs:
    Apply
    Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) (NCT01483144)
    Phase 3
    Cancer Prevention Pharmaceuticals, Inc.
    Completed
    Last update posted :
    06/08/2021
    Initiation :
    10/01/2013
    Primary completion :
    11/01/2018
    Completion :
    03/01/2019
    APC
    |
    APC mutation
    |
    Flynpovi (eflornithine/sulindac)